Taysha Gene Therapies Retained Earnings (Accumulated Deficit) 2020-2024 | TSHA
Taysha Gene Therapies retained earnings (accumulated deficit) from 2020 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Taysha Gene Therapies Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$-513 |
| 2022 |
$-401 |
| 2021 |
$-236 |
| 2020 |
$-61 |
| 2019 |
$-1 |
Taysha Gene Therapies Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-06-30 |
$-558 |
| 2024-03-31 |
$-537 |
| 2023-12-31 |
$-513 |
| 2023-09-30 |
$-561 |
| 2023-06-30 |
$-444 |
| 2023-03-31 |
$-419 |
| 2022-12-31 |
$-401 |
| 2022-09-30 |
$-346 |
| 2022-06-30 |
$-320 |
| 2022-03-31 |
$-286 |
| 2021-12-31 |
$-236 |
| 2021-09-30 |
$-185 |
| 2021-06-30 |
$-134 |
| 2021-03-31 |
$-93 |
| 2020-12-31 |
$-61 |
| 2020-09-30 |
$-43 |
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.490B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
